These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 20223672

  • 1. A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration.
    Souayah N, Khella SL.
    J Clin Neurosci; 2010 May; 17(5):571-3. PubMed ID: 20223672
    [Abstract] [Full Text] [Related]

  • 2. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E, Tosi P, Cangini D, Tacchetti P, Salvi F, Bartolomei I, Michelucci R, Tassinari CA.
    Neurology; 2007 Aug 07; 69(6):573-81. PubMed ID: 17679676
    [Abstract] [Full Text] [Related]

  • 3. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
    Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM.
    J Clin Oncol; 2006 Sep 20; 24(27):4507-14. PubMed ID: 16940275
    [Abstract] [Full Text] [Related]

  • 4. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
    Maurer T, Poncelet A, Berger T.
    Arch Dermatol; 2004 Jul 20; 140(7):845-9. PubMed ID: 15262695
    [Abstract] [Full Text] [Related]

  • 5. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2).
    Van Brakel WH, Anderson AM, Withington SG, Croft RP, Nicholls PG, Richardus JH, Smith WC.
    Lepr Rev; 2003 Dec 20; 74(4):300-10. PubMed ID: 14750575
    [Abstract] [Full Text] [Related]

  • 6. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
    Kocer B, Sucak G, Kuruoglu R, Aki Z, Haznedar R, Erdogmus NI.
    Acta Neurol Belg; 2009 Jun 20; 109(2):120-6. PubMed ID: 19681443
    [Abstract] [Full Text] [Related]

  • 7. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
    Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Genève J, Maraninchi D.
    J Clin Oncol; 2007 Sep 01; 25(25):3945-51. PubMed ID: 17761978
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.
    Lizogub VG, Riley DS, Heger M.
    Explore (NY); 2007 Sep 01; 3(6):573-84. PubMed ID: 18005909
    [Abstract] [Full Text] [Related]

  • 9. Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis.
    Pulido JS, Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group.
    Trans Am Ophthalmol Soc; 2002 Sep 01; 100():85-106; discussion 106-7. PubMed ID: 12545682
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
    Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, Rosenthal M, Chia M, Michael M, Bartley P, Harrison L, Daly M.
    Clin Cancer Res; 2005 Mar 01; 11(5):1890-8. PubMed ID: 15756015
    [Abstract] [Full Text] [Related]

  • 11. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
    Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M.
    Eur J Haematol; 2005 Mar 01; 74(3):212-6. PubMed ID: 15693790
    [Abstract] [Full Text] [Related]

  • 12. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GR.
    Am J Med; 2005 Mar 01; 118(3):246-50. PubMed ID: 15745722
    [Abstract] [Full Text] [Related]

  • 13. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
    Drenth JP, Vonk AG, Simon A, Powell R, van der Meer JW.
    J Pharmacol Exp Ther; 2001 Sep 01; 298(3):1221-6. PubMed ID: 11504824
    [Abstract] [Full Text] [Related]

  • 14. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD, Nademanee AP, Negrin RS, Snyder DS, Hu WW, Gould KA, Tierney DK, Zwingenberger K, Forman SJ, Blume KG.
    Biol Blood Marrow Transplant; 1996 May 01; 2(2):86-92. PubMed ID: 9118303
    [Abstract] [Full Text] [Related]

  • 15. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin.
    Guillaume JC, Moulin G, Dieng MT, Poli F, Morel P, Souteyrand P, Bonnetblanc JM, Claudy A, Daniel F, Vaillant L.
    Arch Dermatol; 1995 Sep 01; 131(9):1032-5. PubMed ID: 7661605
    [Abstract] [Full Text] [Related]

  • 16. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.
    Cancer Chemother Pharmacol; 2007 Feb 01; 59(2):165-74. PubMed ID: 16736151
    [Abstract] [Full Text] [Related]

  • 17. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N.
    Am J Ophthalmol; 2008 Feb 01; 145(2):239-248. PubMed ID: 18222192
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T, Chan P, Wong H, Ng KK, Chok SH, Cheung TT, Lam V, Epstein RJ, Fan ST, Poon RT.
    Oncology; 2007 Feb 01; 72 Suppl 1():67-71. PubMed ID: 18087184
    [Abstract] [Full Text] [Related]

  • 19. Childhood thalidomide neuropathy: a clinical and neurophysiologic study.
    Priolo T, Lamba LD, Giribaldi G, De Negri E, Grosso P, De Grandis E, Veneselli E, Buoncompagni A, Viola S, Alpigiani MG, Gandullia P, Calevo MG.
    Pediatr Neurol; 2008 Mar 01; 38(3):196-9. PubMed ID: 18279755
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R.
    Cancer; 2002 Aug 15; 95(4):758-65. PubMed ID: 12209719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.